





In this report, “Array BioPharma,” “Array,” “we,” “us” and “our” refer to Array BioPharma Inc., unless the context otherwise provides.

Item 8.01 Other Events.

On September 29, 2014, Array issued a press release announcing that final results from a Phase 2 trial of binimetinib in patients with advanced NRAS mutant melanoma were presented at the European Society for Medical Oncology Annual Meeting in Madrid, Spain.

A copy of the press release is attached to this Form 8-K as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press release announcing Phase 2 Trial of Binimetinib in NRAS Melanoma Shows Promising Clinical Activity

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 29, 2014

Array BioPharma Inc.

By: /s/ R. Michael Carruthers  
R. Michael Carruthers  
Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release announcing Phase 2 Trial of Binimetinib in NRAS Melanoma Shows Promising Clinical Activity